" class="no-js "lang="en-US"> Congruence Therapeutics - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Congruence Therapeutics | PTF

Congruence Therapeutics

About Congruence Therapeutics

Congruence Therapeutics

Congruence Therapeutics is a drug discovery company that is uniquely harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry.  Our ground-breaking discovery engine, Revenir™, sees proteins in ways others have been unable to see – in their full dynamic state.

Related Story

Drug Development

 Congruence Therapeutics Strengthens Leadership Team with Appointment of Dr. Sharath Hegde as Chief Scientific Officer | PTF

Congruence Therapeutics Strengthens Leadership Team with Appointment of Dr. Sharath Hegde as Chief Scientific Officer

November 23 2022

Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery […]